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ABSTRACT
Controversy exists over whether pretransplantation consolidation chemotherapy affects the outcome of sub-
sequent autotransplantation for acute myelogenous leukemia (AML). The current study was undertaken to
determine the association between previous consolidation and outcome of autotransplantation for AML in first
remission. Posttransplantation outcomes of 146 patients receiving no consolidation were compared with those
of 244 patients receiving standard-dose (<1 gm/m2) and 249 patients receiving high-dose (1-3 gm/m2)
cytarabine, using proportional hazards regression to adjust for differences in prognostic variables. One-year
transplantation-related mortality was similar among the cohorts. Five-year relapse rates were 49% (95%
confidence interval CI}  39%-58%) with no consolidation, 35% (95% CI  29%-42%) with standard-dose
cytarabine, and 40% (95% CI  33%-48%) with high-dose cytarabine (P  .07). Five-year leukemia-free
survival rates were 39% (95% CI  30%-47%) with no consolidation, 53% (95% CI  46%-60%) with
standard-dose cytarabine, and 48% (95% CI  40%-56%) with high-dose cytarabine (P  .03). Similarly,
5-year overall survival was better in those patients receiving consolidation: 42% (95% CI  34%-51%) with no
consolidation, 59% (95% CI  52%-65%) with standard-dose cytarabine, and 54% (95% CI  46%-61%) with
high-dose cytarabine (P  .01). Although most patients received 1 or 2 cycles of consolidation, the number of
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Consolidation before Autotransplantation for AML in First Complete Remission
Bcourses had no detectable effect on transplantation outcome. In multivariate analysis, risks of relapse and
treatment failure were lower in the patients receiving consolidation, especially among those patients receiving
blood cell grafts. Outcomes with standard-dose and high-dose cytarabine were similar. Based on our findings,
we recommend that patients with AML in first remission receive consolidation before undergoing autotrans-
plantation.
© 2006 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Autologous hematopoietic stem cell transplanta-
ion (AuSCT) is an effective treatment for patients
ith acute myelogenous leukemia (AML) in ﬁrst com-
lete remission (CR) [1-6]. Three- to 4-year leuke-
ia-free survival (LFS) with this approach is 45%-
5%. Attempts to improve these results have included
x vivo graft purging techniques [7-9], in vivo purging
trategies, and posttransplantation immunologic ma-
ipulations, such as interleukin-2 or infusion of lym-
hokine-activated killer cells [10-12].
Pretransplantation consolidation chemotherapy,
ften with high-dose cytarabine, is routinely adminis-
ered before high-dose conditioning. The beneﬁts of
uch a strategy are unclear, however. It is possible that
onsolidation chemotherapy before transplantation
ay reduce the leukemic cell burden and thereby
mprove transplantation outcome by reducing post-
ransplantation relapse [5,13]. Alternatively, intensive
onsolidation chemotherapy may result in toxicities
evere enough to preclude transplantation or may in-
rease the risk of transplantation-related morbidity
nd mortality. In the setting of allogeneic stem cell
ransplantation for AML in ﬁrst CR, we previously
ound that pretransplantation cytarabine consolida-
ion did not favorably inﬂuence outcome compared
ith no pretransplantation consolidation [14]. This
ack of beneﬁt may be attributable to potent graft-
ersus-leukemia (GVL) effects of allogeneic trans-
lantation, which may overcome or be less inﬂuenced
y pretreatment patient- or disease-related character-
stics or greater amounts of residual disease. The lack
f such a GVL effect after autotransplantation may
ake intensive pretransplantation consolidation che-
otherapy important. This study was designed to
ompare the outcome of AuSCT recipients receiving
ither no pretransplantation consolidation, standard-
ose cytarabine consolidation, or high-dose cytara-
ine consolidation before high-dose therapy.
ATIENTS AND METHODS
ata Sources
The Autologous Blood and Marrow Transplant
egistry (ABMTR) is a voluntary working group of p
B & M Tore than 250 transplantation centers, primarily in
orth and South America, which contribute detailed
ata on their autologous transplantation recipient to a
tatistical Center at the Health Policy Institute of the
edical College of Wisconsin. Participating centers
re required to register all transplantations consecu-
ively; compliance is monitored by on-site audits. The
atabase of the ABMTR includes 50% of all autol-
gous transplantations performed in North and South
merica since 1990. Patients are followed longitudi-
ally, with yearly follow-up. Computerized checks for
rrors, physician review of submitted data, and on-site
udits of participating centers ensure the quality of the
ata.
The ABMTR collects data at 2 levels: registration
nd research. Registration data include disease type,
ge, sex, pretransplantation disease stage and chemo-
herapy responsiveness, date of diagnosis, graft type
bone marrow– and/or blood-derived stem cells),
igh-dose conditioning regimen, posttransplantation
isease progression and survival, development of a
ew malignancy, and cause of death. Requests for data
n progression or death for registered patients are at
-month intervals. All ABMTR teams contribute reg-
stration data. Research data are collected on subsets
f registered patients and include comprehensive pre-
ransplantation and posttransplantation clinical infor-
ation.
atients
This study included 639 patients undergoing
uSCT for AML in ﬁrst CR between 1989 and 1998,
or whom comprehensive research data were reported
o the ABMTR. During the study period, registration
ata were submitted for an additional 731 patients
eceiving AuSCT for AML in ﬁrst CR. Demographics
nd survival of these patients were similar to those of
he study population. A total of 146 patients received
o pretransplantation consolidation, 244 received
tandard-dose cytarabine consolidation, and 249 re-
eived high-dose cytarabine consolidation before
ransplantation. Additional drugs were included in the
onsolidation regimens of 220 (90%) patients receiv-
ng standard-dose cytarabine and 192 (77%) of the
atients receiving high-dose cytarabine. Standard-
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2ose cytarabine was deﬁned as 1 g/m2/dose; high-
ose cytarabine, as 1-3 g/m2/dose. Chemotherapy
iven for mobilization was counted as consolidation.
he median follow-up of survivors was 49 months,
ncluding 57 months for those receiving no pretrans-
lantation consolidation, 52 months for those receiv-
ng standard-dose cytarabine, and 36 months for those
eceiving high-dose cytarabine.
Cytogenetic abnormalities were divided into those
ssociated with good, intermediate, or poor prognosis.
ytogenetic abnormalities with good prognosis in-
luded t(8;21) with or without other abnormalities,
(15;17) with or without other abnormalities, and inv
r del(16) with or without other abnormalities. Cyto-
enetic abnormalities with intermediate prognosis in-
luded trisomy 8 with or without other abnormalities,
risomy 21 with or without other abnormalities, t(6;9)
ith or without other abnormalities, other transloca-
ions, other numerical abnormalities, and other struc-
ural abnormalities. Cytogenetic abnormalities with
oor prognosis included t(9;22) with or without other
bnormalities; 7 or del(7) with or without other
bnormalities, and del(11) with or without other ab-
ormalities and complex karyotypes [15]. Patients
ith cytogenetic abnormalities of both good and poor
rognosis were considered to be in the poor prognosis
roup.
ndpoints
Primary study endpoints were transplantation-re-
ated mortality (TRM), clinical leukemia relapse (he-
atologic and extramedullary), LFS, and overall sur-
ival. TRM was deﬁned as death during continuous
R posttransplantation. Relapse was deﬁned as clini-
al or hematologic leukemia recurrence. For analyses
f LFS, failures were clinical or hematologic relapses
r deaths from any cause; patients alive and in com-
lete remission were censored at time of last follow-
p. For analysis of overall survival, failure was death
rom any cause; surviving patients were censored at
he date of last contact.
tatistical Analysis
Patient-, disease-, and transplantation-related vari-
bles for patients receiving no postremission therapy,
hose receiving standard-dose cytarabine postremission
herapy, and those receiving high-dose cytarabine post-
emission therapy were compared using the 2 statistic
or categorical variables and the Kruskal-Wallis test for
ontinuous variables. Univariate probabilities of LFS
nd survival were calculated using the Kaplan-Meier
stimator; the log-rank test was used for univariate com-
arisons. Probabilities of TRM and leukemia relapse
ere calculated using cumulative incidence curves to
ccommodate competing risks [16]. Assessment of po-
ential risk factors for outcomes of interest were evalu- t
06ted through multivariate analyses using Cox propor-
ional hazards regression [17]. The variables considered
n multivariable analysis are listed in Table 1.
First, we compared the likelihood from a model
tratiﬁed on pretransplantation consolidation therapy
ith that from a model with different risk coefﬁcients
or each pretransplantation consolidation therapy.
he likelihood ratio test constructed from these mod-
ls determined whether there was any interaction be-
ween pretransplantation consolidation therapy and
he factor being examined. When the likelihood ratio
est was signiﬁcant, an interaction term was added to
he model. After determining interaction terms, we
ext tested for proportional hazards for each factor in
he Cox model using time-dependent covariates.
hen this indicated differential effects over time
nonproportional hazards), we constructed models
reaking the posttransplantation course into 2 time
eriods, using the maximized partial likelihood
ethod to ﬁnd the most appropriate break point.
fter the foregoing modeling of time-varying effects,
e constructed the ﬁnal multivariate model using a
orward stepwise model selection approach. Each
odel contained the main effect for pretransplanta-
ion consolidation therapy (no pretransplantation con-
olidation vs standard-dose cytarabine vs high-dose
ytarabine). However, risks associated with high- and
tandard-dose cytarabine were virtually identical in all
nalyses, and so the ﬁnal models show only the relative
isk (RR) of each outcome for patients receiving any
onsolidation versus those receiving no consolidation.
here was a signiﬁcant interaction between the graft
ype and the effect of consolidation, meaning that
revious consolidation had a different effect depend-
ng on whether the patient received a bone marrow or
eripheral stem cell graft; thus, the comparisons are
tratiﬁed based on graft type. Factors that were sig-
iﬁcant at a 5% level were kept in the ﬁnal model.
ecause the ﬁnal models included previous myelodys-
lastic syndrome as a signiﬁcant factor, 7 patients with
nknown previous myelodysplastic syndrome were ex-
luded in all multivariate analyses. Examination for
enter effects used a random-effects or frailty model
18]. We found no evidence of correlation between
enter effects and any of the outcomes. All P values are
-sided.
ESULTS
atients
Patient-, disease- and transplantation-related vari-
bles are given in Table 2. The median age of the
atients receiving standard-dose cytarabine consolida-
ion was 24 years, younger than those receiving either
o consolidation or high-dose cytarabine consolida-
ion. There was no signiﬁcant difference in gender
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Bistribution. A greater percentage of patients receiv-
ng high-dose cytarabine had a pretransplantation
arnofsky score 90%. The median white blood cell
ount at diagnosis was lower in the no pretransplan-
ation consolidation group than in the standard- and
igh-dose cytarabine groups. There were no differ-
nces in the distribution of good, intermediate, or
oor prognosis cytogenetics among the 3 groups. Ap-
roximately 30% of the patients in each group had
ormal cytogenetics, and 30% had unknown karyo-
ypes. A higher percentage of patients receiving either
o consolidation or standard-dose cytarabine had ex-
ramedullary disease compared with those receiving
igh-dose cytarabine. There were no differences
mong the groups in the percentage of patients with
revious history of myelodysplastic syndrome. Pa-
ients receiving high-dose cytarabine were more likely
o receive only 1 cycle of pretransplantation consoli-
ation than those receiving standard-dose cytarabine.
he time from diagnosis to ﬁrst CR was longer in the
atients receiving no consolidation. Not unexpect-
dly, the time between achieving CR and transplan-
ation was longer for the patients who received con-
olidation. More patients not receiving consolidation
r receiving standard-dose cytarabine had bone mar-
ow as the source of stem cells compared with those
able 1. Variables Tested in Cox Proportional Hazards Regression Mod
Main effect variable*:
Type of pretransplantation consolidation therapy: none versus
Patient-related variables:
Age at transplant: <40 years versus >40 years
Sex: female versus male
Karnofsky performance status pretransplantation: <90% versus
Disease-related variables at diagnosis:
FAB subtype: M1,M2 versus M3 versus M4 versus M5–M7 versu
WBC at diagnosis: <10109/L versus 10-100109/L versus >10
Cytogenetics: good prognosis versus intermediate prognosis ve
Disease-related variables at transplantation:
Extramedullary disease at diagnosis: yes versus no
Previous myelodysplastic syndrome: yes versus no
Induction therapy: 1 cycle standard-dose Ara-C  other versus
other versus >1 cycle high-dose Ara-C  other versus 1 cy
Additional drugs for consolidation: yes versus no
Time from diagnosis to CR1: <2 months versus >2 months ve
Cycles of chemotherapy to achieve CR1: 1 versus >1 versus m
Consolidation chemotherapy cycles after CR1: 1 versus 2 versu
Time from diagnosis to transplantation
Time from CR1 to harvest: <3 months versus >3 months vers
Time from CR1 to transplant: <3 months versus >3 months v
Treatment-related:
Source of stem cell: BM versus PBSC
Conditioning regimen: CyTBI  other versus BuCyVP16  oth
Year of transplantation: 1989-1994 versus 1995-1998
Induction of GVHD: yes versus no versus missing
Growth factors posttransplantation: yes versus no
AB indicates French-American-British classiﬁcation; WBC, white
CR, complete remission; Bu, busulfan; Cy, cyclophosphamide;
disease; GF, growth factors.
Included in all models.eceiving high-dose cytarabine. Purging the graft to
B & M Temove leukemia cells was more likely to be done for
he patients who did not receive consolidation. The
atients who received consolidation with high-dose
ytarabine were more likely to receive either granulo-
yte or granulocyte-macrophage colony-stimulating
actor to promote hematopoietic recovery. Moreover,
7% of patients receiving pretransplantation consoli-
ation received growth factors for harvesting.
nivariate Analyses
Univariate comparisons of outcomes are given in
able 3. One-year TRM rates were similar among the
treatment groups (Figure 1A). The 5-year relapse
ate was 10% lower in the patients receiving consoli-
ation than in those not receiving consolidation (Fig-
re 1B). The 5-year LFS and overall survival were
igniﬁcantly higher in those receiving consolidation
han in those not receiving consolidation.
ultivariate Analyses
In all multivariate analyses, the risk of transplan-
ation outcomes was virtually identical for the stan-
ard- and high-dose cytarabine groups. Consequently,
nly the RR risks with consolidation versus without
onsolidation are presented here.
rd or high-dose cytarabine
versus missing
r/unclassified
/L versus missing
or prognosis versus no abnormalities versus unknown
cle standard-dose Ara-C other versus 1 cycle high-dose Ara-C
er induction therapy versus >1 cycle other induction therapy
issing
ersus missing
sing
issing
sus BuCy  other versus others
cell count; BM, bone marrow; PBSC, peripheral blood stem cells;
otal body irradiation; VP16, etoposide; GVHD, graft-versus-hostels
standa
>90%
s othe
0109
rsus po
>1 cy
cle oth
rsus m
issing
s >2 v
us mis
ersus m
er ver
blood
TBI, tIn multivariate analysis, TRM was higher among
207
Table 2. Characteristics of Patients Receiving Autologous Transplantation for AML in First Complete Remission by Cytarabine (Ara-C) Pretransplantation Consolidation Therapy
Variable
No Pretransplantation
Consolidation Standard-Dose Ara-C High-Dose Ara-C
P value*No. evaluable n (%) No. evaluable n (%) No. evaluable n (%)
Number of patients 146 244 249 —
Age, median (range), years 146 30 (1-70) 244 24 (1-71) 249 38 (1-69) <.001
Age by decade, years 146 244 249 <.001
<10 35 (24) 63 (26) 24 (10)
10-19 18 (12) 42 (17) 28 (11)
20-29 18 (12) 33 (14) 34 (13)
30-39 25 (17) 33 (14) 60 (24)
40-49 20 (14) 43 (17) 44 (18)
>50 30 (21) 30 (12) 59 (24)
Male 146 67 (46) 244 116 (48) 249 131 (53) .356
Karnofsky score pretransplantation <90 135 16 (12) 239 33 (14) 244 56 (23) .006
FAB subtype 146 244 249 .205
Unclassified 13 (9) 9 (4) 10 (4)
M1 20 (14) 27 (11) 34 (14)
M2 29 (20) 76 (31) 64 (26)
M3 16 (11) 18 (7) 22 (9)
M4 25 (17) 57 (24) 64 (26)
M5 30 (21) 40 (16) 36 (14)
M6 6 (4) 4 (2) 6 (2)
M7 5 (3) 8 (3) 7 (3)
Other 2 (1) 5 (2) 6 (2)
WBC at diagnosis, median (range), 109/L 135 11 (<1-453) 209 14 (1-418) 213 15 (<1-255) .557
WBC at diagnosis 135 209 213 .824
<10  109/L 65 (48) 91 (44) 94 (44)
10-100  109/L 61 (45) 99 (47) 98 (46)
>100  109/L 9 (7) 19 (9) 21 (10)
Cytogenetics† 146 244 249 .381
No abnormalities 45 (31) 66 (27) 85 (34)
Good prognosis 15 (10) 33 (14) 30 (12)
Intermediate prognosis 31 (21) 59 (24) 52 (21)
Poor prognosis 10 (7) 8 (3) 17 (7)
Unknown 45 (31) 78 (32) 65 (26)
Extramedullary disease at diagnosis 146 25 (17) 244 37 (15) 249 18 (7) .005
Previous myelodysplastic syndrome 144 9 (6) 241 8 (3) 247 6 (2) .142
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Table 2. Continued
Variable
No Pretransplantation
Consolidation Standard-Dose Ara-C High-Dose Ara-C
P value*No. evaluable n(%) No. evaluable n(%) No. evaluable n(%)
Induction therapy 138 236 235 <.001
1 cycle standard-dose Ara-C  other 29 (21) 120 (51) 109 (46)
>1 cycle standard-dose Ara-C  other 62 (45) 76 (32) 40 (17)
1 cycle high-dose Ara-C  other 19 (14) 3 (1) 53 (23)
>1 cycle high-dose Ara-C  other 4 (3) 2 (1) 17 (7)
1 cycle other therapy 18 (13) 26 (11) 10 (4)
>1 cycle other therapy 6 (4) 9 (4) 6 (3)
Additional drugs for consolidation‡ NA 244 220 (90) 249 192 (77) <.001§
Time from diagnosis to CR1, median (range), months 145 2 (<1-7) 241 1 (<1-6) 240 1 (<1-7) <.001
Time from diagnosis to CR1 >2 months 145 53 (37) 241 71 (29) 240 43 (18) <.001
Cycles of chemotherapy to achieve CR1 138 236 235 <.001
1 66 (48) 149 (63) 172 (73)
2 38 (27) 65 (27) 50 (22)
3 8 (6) 18 (8) 10 (4)
>4 26 (19) 4 (2) 3 (1)
Consolidation chemotherapy cycles after CR1¶ NA 223 207 <0.001§
1 98 (44) 123 (59)
2 93 (42) 51 (25)
>2 32 (14) 33 (16)
Time from diagnosis to transplantation median (range), months 146 4 (2-16) 244 5 (3-48) 249 6 (2-20) <.001
Time from CR1 to harvest, median (range), months 140 2 (<1-5) 235 3 (<1-10) 233 3 (<1-10) <.001
Time from CR1 to transplantation, median (range), months 144 2 (<1-8) 235 4 (<1-11) 237 4 (<1-11) <.001
Source of stem cells 146 244 249 <.001
BM 120 (82) 180 (74) 111 (45)
Peripheral blood 16 (11) 55 (22) 108 (43)
BM  peripheral blood 10 (7) 9 (4) 30 (12)
Purging 146 121 (83) 244 92 (38) 249 39 (16) <.001
Agents used for purging —
Monoclonal antibody 3 (2) 1 (1) 3 (8)
4-hydroperoxycyclophosphamide 88 (73) 79 (86) 26 (67)
Mafosfamide 0 3 (3) 1 (2)
Other# 11 (9) 6 (7) 3 (8)
Conditioning regimen 146 244 249 .001
CyTBI  other 13 (9) 29 (12) 23 (9)
BuCyVP16  other 4 (3) 18 (7) 18 (7)
BuCy  other (not VP16) 107 (73) 146 (60) 131 (53)
Other 22 (15) 51 (21) 77 (31)
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Table 2. Continued
Variable
No Pretransplantation
Consolidation Standard-Dose Ara-C High-Dose Ara-C
P value*No. evaluable n(%) No. evaluable n(%) No. evaluable n(%)
Year of transplant 146 244 249 <.001
1989 24 (16) 16 (7) 2 (1)
1990 14 (9) 17 (7) 10 (4)
1991 13 (9) 35 (14) 23 (9)
1992 23 (16) 37 (15) 21 (9)
1993 33 (23) 27 (11) 30 (12)
1994 16 (11) 40 (16) 17 (7)
1995 10 (7) 28 (11) 30 (12)
1996 9 (6) 16 (7) 37 (15)
1997 4 (3) 17 (7) 38 (15)
1998 0 11 (5) 41 (16)
Induction of GVHD/immunotherapy 143 14 (10) 220 16 (7) 238 5 (2) .004
G-CSF or GM-CSF given within 7-days posttransplantation 146 24 (16) 244 67 (27) 249 139 (56) <.001
AML indicates acute myelogenous leukemia; Ara-C, cytosine arabinoside; FAB, French-American-British classiﬁcation; WBC, white blood cell count; BM, bone marrow; CR, complete remission; NA,
not applicable; SDAC, standard-dose Ara-C; HDAC, high-dose Ara-C; Bu, busulfan; IL-2, interleukin-2; Cy, cyclophosphamide; TBI, total body irradiation; VP16, etoposide; GF, growth factors;
G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor.
*The 2 test was used for discrete covariates; the Kruskal-Wallis test was used for continuous covariates.
†Good prognosis includes 16q, t(8;21), t(15;17). Intermediate prognosis includes8,21, t(1;7), t(6;9), t(8;16), other abnormalities. Poor prognosis includes5/5q,7/7q,20/20q, 3q, 11q,
t(5;7), t(9;22).
‡Additional drugs used for consolidation in the standard-dose Ara-C group were: mitoxantrone (23); daunorubicin (54); idarubicin (50); 6-thioguanine (22); doxorubicin (6); idarubicin6-thioguanine
(5); mitoxantrone6-thioguanine (3); mitoxantroneidarubicin (5); danuorubicin6-thioguanine (26); daunorubicin mitoxantrone 6-thioguanine (1) and others (25). Additional drugs used for
consolidation in the high-dose Ara-C group were: mitoxantrone (85); daunorubicin (27); idarubicin (24); doxorubicin (2); idarubicin6-thioguanine (3); mitoxantrone6-thioguanine (1);
daunorubicinmitoxantrone (1); daunorubicin6-thioguanine (10); danuorubicinmitoxantrone 6-thioguanine (1) and others (38).
§Probability of testing standard-dose versus high-dose Ara-C.
¶For those who received consolidation therapy.
#Other agents used for purging were: etoposide, antisense oligonucleotide, edelfosine, and other drugs.
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Batients who received cytarabine alone for consolida-
ion before autologous peripheral blood stem cell
rafting. Among patients who received autologous
one marrow transplantation, TRM did not differ
able 3. Univariate Analysis of Transplantation Outcomes in Patients
y Ara-C Pretransplantation Consolidation Therapy
No Pretransplantation
Consolidation Stan
Outcome event No. evaluable
Probability
(95% CI)* No. eva
00-day mortality 146 12 (8-18) 24
RM 144 23
At 1 year 8 (4-13)
At 3 years 10 (6-16)
At 5 years 12 (7-18)
elapse 144 23
At 1 year 37 (29-46)
At 3 years 47 (37-56)
At 5 years 49 (39-58)
FS 144 23
At 1 year 54 (46-62)
At 3 years 42 (34-51)
At 5 years 39 (30-47)
verall survival 146 24
At 1 year 63 (55-71)
At 3 years 46 (38-54)
At 5 years 42 (34-51)
ML indicates acute myelogenous leukemia; Ara-C, cytosine arabin
conﬁdence interval.
Probabilities of leukemia-free survival and overall survival were cal
were calculated using the cumulative incidence estimate.
The log-rank test was used for univariate comparisons between g
Pointwise P value was used for univariate comparisons between g
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igure 1. Cumulative incidences of TRM (A) and relapse (B) after
utologous bone marrow (BM) or PBSC transplantation for AMLan ﬁrst CR by pretransplantation cytarabine consolidation therapy.
B & M Tigniﬁcantly between patients who did receive or did
ot receive pretransplantation consolidation (Table
). The only factor associated with increased risk of
RM was French-American-British (FAB) classiﬁca-
ion. We found no statistically signiﬁcant difference
etween pretransplantation consolidation therapy and
urging, such that outcomes do not differ based on
retransplantation consolidation therapy and purging.
After both bone marrow and peripheral blood
tem cell grafting, the risk of relapse was lower in the
atients who received cytarabine consolidation than in
hose who did not receive consolidation, although the
ffect of pretransplantation consolidation was greater
n patients receiving peripheral blood stem cell grafts
Table 5) (P .001).
Previous consolidation was associated with a
ower risk of treatment failure (relapse or death)
ith both graft types, but the effect was greater and
he association stronger in those patients receiving
eripheral blood stem cell grafting (Table 6; Figure
A; P .001). Other factors associated with LFS
ere FAB classiﬁcation and time from diagnosis to
rst CR.
Similarly, the risk of death was lower in patients
ho received standard-dose or high-dose cytarabine
ompared with those who did not receive pretrans-
lantation consolidation (Table 7; Figure 2B). Other
actors associated with survival were FAB classiﬁcation
g Autologous Transplantation for AML in First Complete Remission
ose Ara-C High-Dose Ara-C
Probability
(95% CI)* No. evaluable
Probability
(95% CI)* P Value†
10 (6-14) 249 6 (3-9) .098
243
9 (6-13) 6 (4-10) .451‡
11 (7-15) 8 (5-12) .641‡
11 (8-16) 11 (7-16) .987‡
243
25 (20-31) 28 (22-34) .064‡
34 (28-41) 37 (30-44) .090‡
35 (29-42) 40 (33-48) .072‡
243 .020†
65 (59-71) 66 (60-72) .047‡
55 (49-61) 55 (48-61) .034‡
53 (46-60) 48 (40-56) .033‡
249 .007†
73 (68-79) 75 (69-80) .050‡
61 (55-67) 63 (56-69) .005‡
59 (52-65) 54 (46-61) .012‡
RM, treatment- related mortality; LFS, leukemia-free survival; CI,
using the Kaplan-Meier product limit estimate. TRM and relapseReceivin
dard-D
luable
4
8
8
8
4
oside; T
culated
roups.nd previous myelodysplastic syndrome.
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2ISCUSSION
Our study shows that consolidation with cytara-
ine before undergoing AuSCT for AML in ﬁrst CR
ecreases the risks of relapse and treatment failure.
his beneﬁt was greatest in the recipients of periph-
ral blood stem cell autografts. Mehta et al. [19] re-
orted conceptually similar results. In contrast, Cahn
t al. [20] found no effect of the cytarabine dose used
or consolidation on transplantation outcome; how-
ver, only 43 of the 841 patients in their study (5%)
id not receive consolidation.
In the current study it was somewhat surprising, in
iew of the similarity in TRM and reportedly better
ntileukemia effects of higher doses of cytarabine in
onventional AML therapy, that outcome did not dif-
er between the standard-dose and high-dose cytara-
ine groups. It is possible that the high doses of
hemotherapy given with autotransplantation produce
imilarly favorable outcomes in patients once a mini-
able 4. Multivariate Analysis of Transplantation-Related Mortality in
Variable* n
retransplantation consolidation therapy*
Bone marrow graft
No pretransplantation consolidation 1
Standard or high-dose cytarabine alone
Standard or high-dose cytarabine  other§ 2
Peripheral blood stem cell graft
No pretransplantation consolidation
Standard or high-dose cytarabine alone
Standard or high-dose cytarabine  other§ 1
ther significant covariates
AB classification
M1, M2 2
M3
M4 1
M5, M6, M7 1
Other/unclassified
I indicates conﬁdence interval; FAB, French-American-British cla
Model stratiﬁed on year of transplantation.
Two degrees of freedom.
Reference group.
Other drugs were daunorubicin, doxorubicin, idarubicin, mitoxan
Four degrees of freedom.
able 5. Multivariate Analysis of Relapse in Patients Receiving Autolog
Variables
retransplantation consolidation therapy*
Bone marrow graft
No pretransplantation consolidation 1
Standard or high-dose cytarabine 2
Peripheral blood stem cell graft
No pretransplantation consolidation
Standard or high-dose cytarabine 1
I indicates conﬁdence interval.
Model stratiﬁed on previous myelodysplastic syndrome.
Reference group.
12al residual leukemia state has been achieved with any
ose of postremission chemotherapy. The reason for
he apparent lack of a dose-response relationship is
ot clear; however, it may be that the high dose of
hemotherapy administered with the transplantation
verwhelms any dose effect of the pretransplantation
onsolidation. We also studied the effect of pretrans-
lantation consolidation therapy according to age
roup (age 19 years vs 19 years) and found no
tatistically signiﬁcant interaction between pretrans-
lantation consolidation therapy and age (data not
hown). Our results in autotransplantation recipients
iffer from our ﬁndings in allotransplantation recipi-
nts, in whom potent GVL effects add to the antileu-
emia effects of high-dose conditioning [14]. In the
atter setting, previous consolidation therapy was not
ssociated with posttransplantation outcome. In the
bsence of a GVL effect after autotransplantation,
ostremission consolidation chemotherapy before
ts Receiving Autologous Transplantation for AML in First CR
Relative Risk (95% CI) P Value
P†overall  .24
1.00‡ P12  .15
2.05 (0.77-5.51) P13  .98
0.98 (0.48-2.05) P23  .10
P†overall  .005
1.00‡ P12  .75
1.21 (0.38-3.87) P13  .027
0.29 (0.10-0.87) P23  .003
1.00‡ P¶overall  .032
0.41 (0.09-1.76) .23
2.11 (1.15-3.86) .016
1.15 (0.56-2.36) .71
2.13 (0.90-5.09) .09
ion.
-thioguanine and etoposide.
ansplantation for AML in First CR
Relative Risk
(95% CI) P Value
1.00†
0.71 (0.51-1.00) .051
1.00†
0.36 (0.21-0.63) <.001Patien
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Consolidation before Autotransplantation for AML in First Complete Remission
BuSCT appears to be important. Furthermore, with
ncreasingly lower rates of TRM, the favorable im-
act of pretransplantation consolidation on leuke-
ia recurrence may translate to a long-term survival
eneﬁt [21].
Several limitations of this study deserve comment.
irst, the decision to use postremission therapy was
able 6. Multivariate Analysis of Leukemia-free Survival in Patients
Variables n
retransplantation consolidation therapy
Bone marrow graft
No pretransplantation consolidation 117
Standard or high-dose cytarabine 285
Peripheral blood stem cell graft
No pretransplantation consolidation 25
Standard or high-dose cytarabine 192
ther significant covariates
AB classification
M1, M2 240
M3 54
M4 140
M5, M6, M7 141
Other/unclassified 44
ime from diagnosis to CR1
<2 months 447
>2 months 160
Missing 12
I indicates conﬁdence interval; FAB, French-American-British cla
Reference group.
Four degrees of freedom.
Two degrees of freedom.
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igure 2. Adjusted probabilities of LFS (A) and overall survival (B)
fter autologous bone marrow (BM) or PBSC transplantation for
ML in ﬁrst CR by cytarabine pretransplantation consolidationcherapy.
B & M Tossibly not random. Patients at highest risk for leu-
emia relapse may have received postremission ther-
py more often than those believed to be not at high
isk for relapse. However, this should have biased the
utcome in favor of the no consolidation cohort. In
act, patients receiving no pretransplantation consoli-
ation appear to be at higher risk, with trends (some
tatistically signiﬁcant) toward more extramedullary
isease, more previous myelodysplasia, and, impor-
antly, a requirement for more cycles of chemotherapy
o achieve CR. We examined these covariates in mul-
ivariate analyses and found that none was statistically
igniﬁcant. In addition, we repeated the analyses re-
tricting the population to those patients achieving
R after 1 or 2 cycles of induction therapy and found
hat the RRs of all outcomes were virtually identical
data not shown). Unfortunately, a signiﬁcant number
f patients in both groups lacked cytogenetic data.
iven the recent evidence that high-dose cytarabine
ay be particularly effective in core-binding factor
eukemias, further analyses of outcome by subsets
ithin cytogenetic risk groups would have been useful
22,23]. We also did not ﬁnd any statistically signiﬁ-
ant interaction between pretransplantation consoli-
ation therapy and whether the patient had de novo or
econdary AML.
Another limitation of the current study is that the
atient groups were heterogeneous. There were other
reatment differences among the cohorts. There may
ave been differences in anthracycline doses. Most
83%) patients in the no consolidation group received
one marrow treated in vitro to remove leukemia
g Autologous Transplantation for AML in First CR
Relative Risk of Death or Relapse
(95% CI) P Value
1.00*
0.73 (0.54-0.99) .048
1.00*
0.40 (0.25-0.65) <.001
1.00* P†overall  .031
0.44 (0.26-0.75) .003
1.12 (0.84-1.50) .45
0.98 (0.73-1.33) .92
0.92 (0.57-1.47) .72
1.00* P‡overall  .041
1.34 (1.03-1.72) .027
0.54 (0.17-1.69) .29
ion; CR, complete remission.Receivin
ssiﬁcatells, which has been associated with a lower relapse
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2isk than the use of blood cell grafts [24]. Again, this
hould have biased the outcome in favor of the no
onsolidation cohort.
A third study limitation was the longer interval
rom remission to autotransplantation in the patients
n the consolidation groups, which may have intro-
uced lead-time bias. That is, the longer interval from
rst CR to graft harvest and autotransplantation may
ave led to the exclusion of patients who relapsed
arly after induction. We tried to explore this issue in
ways. First, we considered time from ﬁrst CR to
ransplantation and from diagnosis to transplantation
s covariates in the Cox regression models. We found
hat neither of these covariates was statistically signif-
cant, and also that including them did not affect the
ssociation between consolidation and outcome. Sec-
nd, we repeated the analyses restricting the popula-
ion to patients undergoing transplantation within 4
onths of achieving CR. Although this greatly de-
reased the size of the consolidation group, the RRs of
ransplantation outcomes were similar. The RR of
reatment failure for standard or high-dose cytarabine
ersus no pretransplantation consolidation was 0.90
95% conﬁdence interval [CI]  0.63-1.30) (P  .58)
or bone marrow grafting and 0.40 (95% CI  0.23-
.72) (P .002) for peripheral blood stem cell (PBSC)
rafting. The RR of overall mortality for standard or
igh-dose cytarabine versus no pretransplantation
onsolidation was 0.79 (95% CI  0.54-1.16) (P 
23) for bone marrow grafting and 0.35 (95% CI 
.19-0.62) (P   .001) for PBSC grafting.
A fourth limitation is that the patients receiving
igh-dose cytarabine consolidation were treated more
ecently, and it is possible that their improved out-
able 7. Multivariate Analysis of Survival in Patients Receiving Autol
Variables* n
retransplantation consolidation therapy*
Bone marrow graft
No pretransplantation consolidation 119
Standard or high-dose cytarabine 290
Peripheral blood stem cell graft
No pretransplantation consolidation 25
Standard or high-dose cytarabine 198
ther significant covariates
AB classification
M1, M2 249
M3 56
M4 142
M5, M6, M7 141
Other/unclassified 44
revious myelodysplastic syndrome
No 609
Yes 23
I indicates conﬁdence interval; FAB, French-American-British cla
Model stratiﬁed on extramedullary disease at diagnosis.
Reference group.
Four degrees of freedom.ome compared with that of the no consolidation s
14roup was inﬂuenced in part by advances in supportive
are and more frequent use of PBSCs as the source of
ematopoietic reconstitution. Finally, the conclusions
rawn here apply only to patients who remain in ﬁrst
R sufﬁciently long to receive autotransplantation; it
s not an intention-to-treat analysis. For these reasons,
t is important that the results of this study be con-
rmed in a randomized clinical trial. The data pro-
ided here will be important to consider in planning
uch a trial. In addition, this study does not establish
he optimal dose or schedule of cytarabine to admin-
ster before autotransplantation. Although most pa-
ients received 1 or 2 cycles of consolidation, the
umber of courses administered had no detectable
ffect on transplantation outcome.
Despite the absence of postremission therapy in 1
ohort, the 5-year LFS was 40%. Furthermore, the
ack of a major difference in LFS among patients
eceiving standard-dose and high-dose cytarabine and
he relapse rate of 35%-40% suggests that future
fforts might be focused on novel posttransplantation
trategies to prevent relapse rather than on simply
ore intensive pretransplantation or posttransplanta-
ion chemotherapy.
Although this study demonstrates a beneﬁt of in-
ensive consolidation before autologous transplanta-
ion for AML in ﬁrst CR, historically randomized
rials have not shown a beneﬁt of autologous trans-
lantation compared with intensive consolidation che-
otherapy. This may be due in part be due to the
elatively high early TRM rate at the time that these
rials were conducted (approximately 15% vs 10% in
he current study), which may have muted the poten-
ial beneﬁt in outcome. The results presented herein
ransplantation for AML in First CR
Relative Risk of Death (95% CI) P Value
1.00†
0.70 (0.51-0.97) .031
1.00†
0.38 (0.24-0.62) <.001
1.00† P‡overall  .012
0.44 (0.24-0.81) .008
1.30 (0.96-1.76) .10
1.16 (0.85-1.59) .35
0.99 (0.58-1.61) .90
1.00†
1.99 (1.16-3.40) .012
ion.ogous T
ssiﬁcatuggest that patients undergoing AuSCT for AML in
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Consolidation before Autotransplantation for AML in First Complete Remission
Brst CR may beneﬁt from additional postremission
hemotherapy before high-dose therapy, with reduced
elapse and treatment failure. This effect is particu-
arly apparent among patients receiving stem cells
rocured from the peripheral blood rather than from
he bone marrow. We found no advantage of high-
ose cytarabine over standard-dose cytarabine. Thus,
atients may reasonably receive consolidation with
ither standard or high-dose cytarabine, based on lo-
al institutional standards, before AuSCT for AML in
rst CR, although prospective studies evaluating the
ole of postremission therapy and optimal schedules
nd doses are still needed.
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